World Conference on Lung Cancer

Letter from The Editor

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

New standard of care in extensive-stage small-cell lung cancer

Next generation immunotherapy in non-small-cell lung cancer

Combination therapies: Where are we in 2018?

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Unmet needs in surgical management of malignant pleural mesothelioma

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement

Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer

Small-cell lung cancer circulating tumour cell derived explants

Spread through air spaces is prognostic in lung neuroendocrine tumours